Condition (MeSH)
Erythroplasia
ClinicalTrials.gov lists 13 trials for Erythroplasia or a narrower condition beneath it. Proteocyte Diagnostics Inc. has the most among industry and government lead sponsors, with 2.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
13 of the 13 trials are tagged with Erythroplasia itself; the rest are tagged with a narrower condition beneath it.
When did Erythroplasia trials start? (9)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Not applicable
- Observational
Top of scale: 3
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2024 | 1 |
| 2023 | 3 |
| 2022 | 2 |
| 2020 | 1 |
| 2019 | 1 |
| 2016 | 1 |
| 2015 | 1 |
| 2007 | 2 |
| 2004 | 1 |
No forecast is made for this condition: it averages 1.2 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 1 trial still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Erythroplasia trials in? (5)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 2 |
| Phase 1/2 | 1 |
| Phase 2 | 3 |
| Not applicable | 2 |
| Observational | 5 |
How many Erythroplasia trials are recruiting? (6)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Recruiting | 3 |
| Active, not recruiting | 3 |
| Completed | 3 |
| Terminated | 2 |
| Withdrawn | 1 |
Showing 5 of 6 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Erythroplasia trials? (4)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Proteocyte Diagnostics Inc. | 2 |
| Instituto Nacional de Cancer, Brazil | 1 |
| National Cancer Institute (NCI) | 1 |
| Skyline Biosciences | 1 |
Interventions as named in the registry (5)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| 1% Metformin | 3 |
| Biopsy | 2 |
| 20 % Aminolevulinic Acid | 1 |
| Metil 5-aminolevulinate | 1 |
| SBS-101 | 1 |
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Erythroplasia trials report? (2)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Oral pain | 1 | 1 |
| oral pain | 1 | 1 |
Which publications cover Erythroplasia? (11)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Prevalence of oral potentially malignant disorders: A systematic review and meta-analysis. | Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology | 2018 | Yes |
| Potentially malignant disorders of the oral and oropharyngeal mucosa; present concepts of management. | Oral oncology | 2010 | Yes |
| Oral erythroplakia--a review. | Oral oncology | 2005 | Yes |
| Early diagnosis of oral cancer: the erythroplastic lesion in high risk sites. | CA: a cancer journal for clinicians | 1978 | Yes |
| Prevalence and factors associated with oral potentially malignant disorders in Brazil's rural workers. | Oral diseases | 2016 | No |
Showing 5 of 11 publications.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence, rare-disease identity, and sub-conditions in mesh.